FDA opposition to legislation that would loosen conflict of interest rules does not seem to be deterring congressional efforts to include it in the Prescription Drug User Fee Act reauthorization.
Commissioner Margaret Hamburg reiterated the agency position that it did not think a bill would help during a Feb
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?